Eli Lilly (NYSE: LLY) stock has been a top performer thanks to runaway sales of its diabetes-turned-weight-management treatment.

Despite nearly doubling over the past 12 months, Eli Lilly stock still has heaps of upside according to investment bank analysts who follow the century-old pharmaceutical giant. Barclay's, an investment bank, recently raised its price target on the pharma giant to $913 per share.

At recent prices, a $913 per-share target suggests Lilly stock could climb about 17% over the next 12 months. Let's look at the reasons why Wall Street's still bullish for this high-flying stock to see if it's a smart buy now for everyday investors.

Continue reading

Source Fool.com